Global Health

Which are the latest news on Global Health?

Why is Global Health Ltd falling/rising?

As of 05-Sep, Global Health Ltd's stock price is rising to 1,468.85, reflecting a 3.52% increase due to a trend reversal, strong relative performance, and high institutional holdings. The stock's bullish indicators and net-debt free status further enhance investor confidence.

As of 05-Sep, Global Health Ltd's stock price is rising, currently at 1,468.85, reflecting a change of 50.0 or 3.52% increase. This upward movement can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after three consecutive days of decline, which indicates a potential recovery in investor sentiment. Additionally, the stock has outperformed its sector by 5.43% today, suggesting strong relative performance compared to peers.<BR><BR>The stock is also trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is typically a bullish sign. Furthermore, it is only 4.33% away from its 52-week high of Rs 1542, indicating that it is approaching a peak level, which can attract more buyers.<BR><BR>Institutional holdings are notably high at 26.35%, with an increase of 1.44% over the previous quarter. This suggests that knowledgeable investors are confident in the company's fundamentals, which can positively influence retail investor sentiment. The company is also net-debt free, which is a favorable financial position that can enhance investor confidence.<BR><BR>Despite a decline in delivery volume by 31.44% against the 5-day average, the stock remains liquid enough for trading, indicating that there is still sufficient interest in the stock. Overall, the combination of positive performance metrics, strong institutional support, and a solid financial position contributes to the rising stock price of Global Health Ltd.

Who are in the management team of Global Health?

The management team of Global Health includes Naresh Kumar Trehan (Chairman & Managing Director), Pankaj Prakash Sahni (Group CEO), and several independent and non-executive directors, bringing diverse expertise to the company.

The management team of Global Health includes the following key individuals:<BR><BR>1. **Naresh Kumar Trehan** - Chairman & Managing Director<BR>2. **Pankaj Prakash Sahni** - Group CEO & Whole-Time Director<BR>3. **Hari S Bhartia** - Independent Non-Executive Director<BR>4. **Praveen Mahajan** - Independent Non-Executive Director<BR>5. **Rajan Bharti Mittal** - Independent Non-Executive Director<BR>6. **Ravi Gupta** - Independent Non-Executive Director<BR>7. **Ravi Kant Jaipuria** - Non-Executive Director (Nominated)<BR>8. **Sunil Sachdeva** - Non-Executive Director<BR>9. **Venkatesh Ratnasami** - Non-Executive Director (Nominated)<BR>10. **Vikram Singh Mehta** - Independent Non-Executive Director<BR><BR>This diverse team brings a range of expertise and guidance to the company.

What does Global Health do?

Global Health Ltd provides healthcare services in the hospital industry and became a public company in 2021. As of June 2026, it reported net sales of 1,304 Cr and a net profit of 159 Cr, with a market cap of INR 39,540 Cr.

Overview: <BR>Global Health Ltd is engaged in providing healthcare services and operates within the hospital industry, categorized as a small-cap company.<BR><BR>History: <BR>Global Health Ltd was incorporated as Global Health Private Limited in 2004. It transitioned to a public limited company on August 11, 2021. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,304 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 159 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 39,540 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 70.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.03% <BR>Debt-Equity: -0.13 <BR>Return on Equity: 14.88% <BR>Price to Book: 10.03<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Global Health?

Global Health's peers include Apollo Hospitals, Max Healthcare, Fortis Health, Aster DM Quality, Narayana Hrudaya, Krishna Institute, Dr. Agarwal's Health, and Rainbow Child. In terms of management risk, Global Health is rated as good, with excellent capital structure, and a 1-year return of 7.83%, which is higher than Max Healthcare but lower than Aster DM Quality's 25.77%.

Peers: The peers of Global Health are Apollo Hospitals, Max Healthcare, Fortis Health., Aster DM Quality, Narayana Hrudaya, Krishna Institu., Dr Agarwal's Hea, and Rainbow Child.<BR><BR>Quality Snapshot: Excellent management risk is observed at Apollo Hospitals, Narayana Hrudaya, and Rainbow Child., while Good management risk is found at Global Health, Aster DM Quality, Krishna Institu., and the rest. Average management risk is present at Max Healthcare and Dr Agarwal's Hea, while Fortis Health. has Average management risk. Growth is Excellent at Apollo Hospitals and Narayana Hrudaya, Good at Fortis Health., Dr Agarwal's Hea, and Global Health, while Average growth is noted at Aster DM Quality, and Below Average growth is seen at Krishna Institu. and Rainbow Child. Capital Structure is Excellent at Global Health, while Average is found at Aster DM Quality and the rest, with Good capital structure at Apollo Hospitals, Narayana Hrudaya, Fortis Health., Max Healthcare, Dr Agarwal's Hea, and Krishna Institu.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aster DM Quality at 25.77%, while the lowest is Max Healthcare at -11.72%. Global Health's 1-year return is 7.83%, which is higher than Max Healthcare but lower than Aster DM Quality. Additionally, Fortis Health. and Max Healthcare have negative six-month returns.

How big is Global Health?

As of 31st August, Global Health Ltd has a market capitalization of 39,540.00 Cr, with net sales of 4683.41 Cr and a net profit of 556.18 Cr over the latest four quarters.

As of 31st August, Global Health Ltd has a market capitalization of 39,540.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Global Health reported net sales of 4683.41 Cr and a net profit of 556.18 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with shareholder's funds amounting to 3,961.57 Cr and total assets of 5,889.36 Cr.

Are Global Health Ltd latest results good or bad?

Global Health Ltd's latest results show strong revenue growth of 26.50% year-on-year, reaching ₹1,304.05 crores, but net profit declined slightly by 0.18%, and operating margins contracted, raising concerns about profitability and high valuation. Overall, while revenue growth is positive, the challenges in profit margins suggest a cautious outlook for investors.

Global Health Ltd's latest results present a mixed picture. On one hand, the company achieved a significant revenue growth of 26.50% year-on-year, reaching ₹1,304.05 crores, which is its strongest quarterly performance to date. This reflects successful capacity additions and improved patient footfall across its hospital network.<BR><BR>However, the net profit for the quarter was ₹158.73 crores, which represents a slight decline of 0.18% year-on-year, despite the substantial revenue increase. Additionally, the operating margin has contracted from 23.92% to 21.99%, and the PAT margin has dropped from 15.42% to 12.06%. These declines indicate that while the company is expanding its top line, it is struggling to translate that growth into proportional profit, primarily due to rising employee costs and increased interest expenses.<BR><BR>The company's premium valuation, trading at a P/E multiple of 66x, raises concerns about whether the current growth trajectory can sustain investor confidence, especially in light of the margin compression and flat profit growth. Overall, while the revenue growth is a positive sign, the challenges in profitability and high valuation suggest a cautious outlook for investors.

Should I buy, sell or hold Global Health Ltd?

When is the next results date for Global Health Ltd?

The next results date for Global Health Ltd is 30 July 2026.

The next results date for Global Health Ltd is on 30 July 2026.

Is Global Health technically bullish or bearish?

As of December 4, 2025, the market trend is mildly bearish, with bearish signals from the weekly MACD and Bollinger Bands, despite some mixed bullish indicators, suggesting caution in the current environment.

As of 4 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish conditions. The monthly MACD is also mildly bearish, while the daily moving averages show a mildly bullish signal, creating a mixed picture. The KST is bullish on a weekly basis, but the overall trend is influenced by the mildly bearish OBV readings. The Dow Theory reflects a mildly bullish stance on the weekly chart, but with no trend on the monthly. Overall, the bearish indicators outweigh the bullish signals, suggesting caution in the current market environment.

How has been the historical performance of Global Health?

Global Health has shown strong financial growth over the past five years, with net sales increasing from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, alongside significant rises in operating profit and profits before and after tax. Despite challenges in cash flow management, the company has expanded its asset base significantly during this period.

Answer:<BR>The historical performance of Global Health shows a consistent upward trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Global Health's net sales have increased significantly from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 222.85 crore in March 2021 to INR 956.17 crore in March 2025. Profit before tax increased from INR 32.46 crore in March 2021 to INR 647.26 crore in March 2025, while profit after tax rose from INR 28.81 crore to INR 481.32 crore during the same period. The earnings per share (EPS) showed fluctuations, peaking at INR 60.79 in March 2023 before settling at INR 17.92 in March 2025. On the balance sheet, total assets grew from INR 2,666.29 crore in March 2021 to INR 4,733.21 crore in March 2025, while total liabilities increased from INR 2,668.36 crore to INR 4,733.21 crore. The cash flow from operating activities improved from INR 241 crore in March 2021 to INR 623 crore in March 2025, although the net cash flow showed a decline, ending at INR -194 crore in March 2025 compared to INR -78 crore in March 2021. Overall, Global Health has demonstrated robust growth in revenue and profitability, alongside an expanding asset base, despite some challenges in cash flow management.

Is Global Health overvalued or undervalued?

As of November 19, 2025, Global Health is considered very expensive with a PE ratio of 53.76 and high valuation ratios compared to peers, despite a strong three-year return of 189.89%, indicating it is overvalued in the current market.

As of 19 November 2025, the valuation grade for Global Health has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently deemed overvalued. Key ratios highlight this assessment, with a PE ratio of 53.76, a Price to Book Value of 8.70, and an EV to EBITDA of 33.44, all of which are considerably high compared to industry norms.<BR><BR>In comparison to its peers, Global Health's valuation stands out, particularly when looking at Max Healthcare with a PE of 80.06 and Apollo Hospitals at 64.09. This suggests that while Global Health is indeed very expensive, it is relatively more attractive than some of its peers. Notably, the company has shown a strong return of 189.89% over the past three years, outperforming the Sensex's 38.15% return during the same period, which may contribute to its elevated valuation despite the current market conditions.

Who are the top shareholders of the Global Health?

The top shareholders of Global Health include Naresh Trehan with 33.03%, Dunearn Investments (Mauritius) Pte Ltd at 14.86%, 25 mutual fund schemes holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined 11.76%. Individual investors account for 6.53% of the shareholding.

The top shareholders of Global Health include Naresh Trehan, who is the promoter with the highest holding at 33.03%. The highest public shareholder is Dunearn Investments (Mauritius) Pte Ltd, holding 14.86%. Additionally, the company has 25 mutual fund schemes collectively holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined holding of 11.76%. Individual investors account for 6.53% of the shareholding.

Has Global Health declared dividend?

No Dividend History Available